logo
MGNX_Logo
MacroGenics continues to expect to start the Phase 2 portion of the TAMARACK study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer (mCRPC) by year-end 2022. The Company believes that this should enable interim data from the Phase 2 portion of the study in 2024

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2022

By MacroGenics, Inc.
Published - Nov 03, 2022, 04:06 PM ET
Last Updated - Mar 18, 2024, 01:44 PM EDT
  • Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced
  • Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end
  • Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data in first quarter of 2023
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024